Vor Biopharma Inc. (VOR)
| Market Cap | 170.63M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -112.46M |
| Shares Out | 124.54M |
| EPS (ttm) | -1.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 170,230 |
| Open | 1.400 |
| Previous Close | 1.400 |
| Day's Range | 1.370 - 1.410 |
| 52-Week Range | 0.630 - 2.430 |
| Beta | -0.45 |
| Analysts | Strong Buy |
| Price Target | 11.36 (+729.2%) |
| Earnings Date | Mar 19, 2025 |
About VOR
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinic... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for VOR stock is "Strong Buy." The 12-month stock price forecast is $11.36, which is an increase of 729.20% from the latest price.
News
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinica...
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi...
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Direc...
Vor Bio Announces $55.6 Million Private Placement
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Myl...
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101...
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new C...
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by My...
New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies
CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 st...
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming inve...
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June ...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation C...
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March ...
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of ...
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full y...
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi...
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
CAMBRIDGE, Mass., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced today it has dosed the first patient in VBP301, its Phase 1/2...
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi...
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, ...
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended Septe...
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform
CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that preclinical and clinical data supporting the Compa...
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June ...
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow H...
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform
CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, ...
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman Sa...